SaniSure, a developer and manufacturer of single-use technology, has acquired GL Engineering (GLE) of East Hanover, New Jersey. With this acquisition, the company will expand its integrated offering of drug product fill and finish bioprocessing assemblies and capabilities including additional capabilities for drug product filling needles and assemblies. GLE will become the company’s centre of excellence for the development of drug product filling solutions, while SaniSure will extend its sterile manufacturing platform with a focus on final filling.
The acquisition is aimed to bolster each company's technical capabilities, product offering and commercial reach.
"We are very excited about the addition of GLE to our innovative product portfolio," said SaniSure's CEO Thomas J. Hook. "GLE's high-quality, global standards filling needle line represents an important expansion to SaniSure's customer-focused solutions. Drug product filling solutions are a critical step in many of our customers' processes. Having the ability to vertically integrate GLE's solutions is quite unique," Hook added.
Global demand for single-use technology is increasing rapidly with increasing R&D activities, a high level of biotech investments and strong global markets, SaniSure says.
"SaniSure's assembly capabilities and commercial reach will significantly enhance the commercialisation of our unique single-use needle design," said GL Engineering Founder Gerhard Liepold, who will now join SaniSure as the Global Product Manager for Drug Product Filling Solutions. "We are very proud to join the SaniSure team and bring more than two decades of pharmaceutical industry experience with strong engineering and commitment to design innovation in the single-use market."
